Investors and startups are targeting the menopause sector within a $360 billion [1] women’s health market that was previously ignored by major pharmaceutical firms.
This shift marks a reversal of 20 years of medical neglect. Because menopause affects half the world's population [2], the lack of targeted treatment has created significant productivity losses and a massive untapped commercial opportunity.
For 20 years, the pharmaceutical and biotech industries largely overlooked the specific needs of women in midlife. This gap left a vacuum that is now being filled by venture capital and specialized startups. Firms such as Stripes and Midi Health, along with celebrities like Naomi Watts, are bringing visibility to the condition.
"The condition has gone largely unnoticed by pharma and biotech firms, employers, and investors..." a Bloomberg reporter said [3].
Wall Street is now treating women’s midlife health as a billion-dollar opportunity. Amboy Street Ventures is among the investment groups betting that the demand for menopause solutions will outpace the current supply of medical offerings.
According to a Bloomberg reporter, the $360 billion [1] women’s health market consists of several categories that have been historically overlooked, with menopause being one of the most prominent examples [4].
The surge in interest comes as a growing number of women demand better healthcare outcomes for the transition into menopause. The movement is not limited to the U.S., as global investors seek to monetize the biological reality of aging for women.
“A $360 billion women’s health market is made of several categories that are often overlooked, one of which is menopause.”
The entry of venture capital into menopause care signals a transition from treating menopause as a natural, inevitable decline to viewing it as a manageable medical condition. By framing a public health gap as a 'billion-dollar opportunity,' investors are incentivizing the development of specialized therapeutics and digital health platforms that the traditional pharmaceutical industry failed to prioritize for two decades.
